AI Engines For more Details: Perplexity Kagi Labs You
Opioid Overdose Reversal: Naloxone is a potent opioid antagonist that works by competitively binding to opioid receptors in the brain, displacing opioids and reversing their effects. It is used as an emergency treatment for opioid overdose to rapidly restore normal breathing and consciousness in individuals experiencing respiratory depression or coma due to opioid overdose.
Prevention of Respiratory Depression: Naloxone is administered via injection or nasal spray to individuals at risk of opioid overdose, such as those receiving opioid pain medications for chronic pain management or those with a history of opioid use disorder. Naloxone can prevent respiratory depression and other life-threatening complications associated with opioid overdose.
Combination Therapy: Naloxone is sometimes formulated in combination with opioid medications, such as buprenorphine, to deter misuse and reduce the risk of overdose. For example, Suboxone contains both buprenorphine and naloxone and is used in medication-assisted treatment (MAT) for opioid dependence.
Community Distribution Programs: Naloxone is increasingly being distributed to at-risk individuals, their family members, and caregivers through community-based programs and pharmacies. This widespread availability of naloxone has been shown to save lives by enabling prompt administration in the event of an opioid overdose emergency.
Adverse Effects: While naloxone is generally safe and well-tolerated when used to reverse opioid overdose, it can precipitate opioid withdrawal symptoms, including nausea, vomiting, sweating, agitation, and increased heart rate, in individuals who are physically dependent on opioids. These effects are typically transient and resolve spontaneously.
Other Uses: Naloxone is also being investigated for potential use in the treatment of conditions such as alcohol use disorder, cocaine overdose, and septic shock. Research in these areas is ongoing, and naloxone's efficacy and safety for these indications have not been conclusively established.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bifidobacterium adolescentis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0 | 0 | |
| ADHD | 0.2 | 0.1 | 1 |
| Age-Related Macular Degeneration and Glaucoma | 0 | 0 | |
| Allergic Rhinitis (Hay Fever) | 0 | 0 | 0 |
| Allergies | 0.1 | 0 | 0 |
| Allergy to milk products | 0 | 0 | 0 |
| Alzheimer's disease | 0.1 | 0.2 | -1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.2 | 0.2 | |
| Ankylosing spondylitis | 0 | 0 | 0 |
| Anorexia Nervosa | 0.1 | -0.1 | |
| Antiphospholipid syndrome (APS) | 0 | 0 | |
| Asthma | 0.2 | 0.1 | 1 |
| Atherosclerosis | 0 | 0.3 | 0 |
| Atrial fibrillation | 0.1 | 0.1 | 0 |
| Autism | 0.6 | 0.1 | 5 |
| Barrett esophagus cancer | 0 | 0 | |
| Bipolar Disorder | 0 | 0.1 | 0 |
| Brain Trauma | 0 | 0.1 | 0 |
| Carcinoma | 0.3 | 0.2 | 0.5 |
| Celiac Disease | 0.2 | 0.2 | 0 |
| Cerebral Palsy | 0 | 0.1 | 0 |
| Chronic Fatigue Syndrome | 0.5 | 0.4 | 0.25 |
| Chronic Kidney Disease | 0.3 | 0 | 0 |
| Chronic Lyme | 0.1 | -0.1 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0 | 0 |
| Chronic Urticaria (Hives) | 0 | 0 | |
| Coagulation / Micro clot triggering bacteria | 0 | 0 | 0 |
| Colorectal Cancer | 0.3 | 0 | 0 |
| Constipation | 0 | 0 | 0 |
| COVID-19 | 0.6 | 0.7 | -0.17 |
| Crohn's Disease | 0.3 | 0.2 | 0.5 |
| cystic fibrosis | 0.1 | -0.1 | |
| deep vein thrombosis | 0 | 0 | |
| Depression | 1 | 0.1 | 9 |
| Dermatomyositis | 0 | 0 | 0 |
| Eczema | 0.1 | -0.1 | |
| Endometriosis | 0.1 | 0.1 | 0 |
| Epilepsy | 0.1 | 0.1 | 0 |
| Fibromyalgia | 0 | 0.1 | 0 |
| Functional constipation / chronic idiopathic constipation | 0.1 | 0.4 | -3 |
| gallstone disease (gsd) | 0 | 0 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0 | 0 | |
| Generalized anxiety disorder | 0.1 | -0.1 | |
| Glioblastoma | 0 | 0 | |
| Graves' disease | 0.1 | 0 | 0 |
| Halitosis | 0 | 0 | 0 |
| Hashimoto's thyroiditis | 0.2 | 0.1 | 1 |
| Hidradenitis Suppurativa | 0 | 0 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.1 | 0.1 | 0 |
| hypercholesterolemia (High Cholesterol) | 0.1 | 0.1 | |
| hyperglycemia | 0.1 | -0.1 | |
| Hyperlipidemia (High Blood Fats) | 0 | 0 | |
| hypertension (High Blood Pressure | 0.1 | 0.3 | -2 |
| Hypothyroidism | 0.1 | -0.1 | |
| Hypoxia | 0 | 0 | |
| IgA nephropathy (IgAN) | 0 | 0 | |
| Inflammatory Bowel Disease | 0.3 | 0.1 | 2 |
| Insomnia | 0.1 | 0.1 | 0 |
| Intracranial aneurysms | 0 | 0 | |
| Irritable Bowel Syndrome | 0.2 | 0.1 | 1 |
| Liver Cirrhosis | 0.2 | 0.1 | 1 |
| Long COVID | 0.5 | 0.2 | 1.5 |
| Low bone mineral density | 0 | 0 | |
| Lung Cancer | 0.1 | 0.1 | |
| ME/CFS with IBS | 0 | 0.1 | 0 |
| ME/CFS without IBS | 0.4 | 0.1 | 3 |
| Menopause | 0 | 0 | |
| Metabolic Syndrome | 0.5 | 0.3 | 0.67 |
| Mood Disorders | 1 | 0.2 | 4 |
| multiple chemical sensitivity [MCS] | 0.1 | 0.1 | |
| Multiple Sclerosis | 0.4 | 0.1 | 3 |
| Multiple system atrophy (MSA) | 0 | 0 | 0 |
| Neuropathy (all types) | 0 | 0 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0 | 0.2 | 0 |
| NonCeliac Gluten Sensitivity | 0 | 0 | |
| Obesity | 0.7 | 0.3 | 1.33 |
| obsessive-compulsive disorder | 0.1 | 0.4 | -3 |
| Osteoarthritis | 0.1 | 0.1 | |
| Osteoporosis | 0.1 | 0 | 0 |
| pancreatic cancer | 0.2 | 0.2 | |
| Parkinson's Disease | 0.1 | 0 | 0 |
| Polycystic ovary syndrome | 0 | 0.2 | 0 |
| Postural orthostatic tachycardia syndrome | 0 | 0 | |
| Premenstrual dysphoric disorder | 0 | 0 | |
| Psoriasis | 0 | 0.1 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.2 | 0.2 | 0 |
| Rosacea | 0.2 | 0 | 0 |
| Schizophrenia | 0.3 | 0 | 0 |
| Sjögren syndrome | 0.2 | 0.1 | 1 |
| Sleep Apnea | 0 | 0.1 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0 | 0 | |
| Stress / posttraumatic stress disorder | 0.1 | 0.2 | -1 |
| Systemic Lupus Erythematosus | 0.3 | 0.2 | 0.5 |
| Tic Disorder | 0.1 | 0 | 0 |
| Tourette syndrome | 0 | 0 | |
| Type 1 Diabetes | 0 | 0.1 | 0 |
| Type 2 Diabetes | 0.5 | 0.1 | 4 |
| Ulcerative colitis | 0.1 | 0.2 | -1 |
| Unhealthy Ageing | 0.3 | 0.2 | 0.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.